National Trauma Research Institute, The Alfred Hospital, 89 Commercial Road, Melbourne, VIC 3004, Australia.
Mediators Inflamm. 2012;2012:356494. doi: 10.1155/2012/356494. Epub 2012 Jun 4.
Traumatic brain injury (TBI) is a complex disease in the most complex organ of the body, whose victims endure lifelong debilitating physical, emotional, and psychosocial consequences. Despite advances in clinical care, there is no effective neuroprotective therapy for TBI, with almost every compound showing promise experimentally having disappointing results in the clinic. The complex and highly interrelated innate immune responses govern both the beneficial and deleterious molecular consequences of TBI and are present as an attractive therapeutic target. This paper discusses the positive, negative, and often conflicting roles of the innate immune response to TBI in both an experimental and clinical settings and highlights recent advances in the search for therapeutic candidates for the treatment of TBI.
创伤性脑损伤(TBI)是人体最复杂器官中的一种复杂疾病,其受害者承受着终身衰弱的身体、情感和心理社会后果。尽管临床护理取得了进展,但 TBI 没有有效的神经保护治疗方法,几乎每一种在实验中显示出前景的化合物在临床上都得到了令人失望的结果。复杂而高度相互关联的固有免疫反应既控制着 TBI 的有益和有害的分子后果,也是一个有吸引力的治疗靶点。本文讨论了固有免疫反应对 TBI 的积极、消极和经常相互矛盾的作用,以及在寻找 TBI 治疗候选药物方面的最新进展。